American Shared Hospital Services (NYSE American: AMS), a leading provider of stereotactic radiosurgery equipment and advanced radiation therapy cancer treatment services, announced today that it will hold a conference call on March 31, 2026, at 12:00 PM ET to discuss its fourth quarter and full year 2025 financial results. The earnings press release will be issued before the market opens the same day.
The teleconference provides investors and analysts an opportunity to hear directly from management about the company's performance and strategic initiatives. Participants in the United States can dial 1-844-413-3972, while international callers should dial 1-412-317-5776, at least ten minutes prior to the start of the call. A simultaneous webcast will be accessible through the company's website at www.ashs.com or directly via this link.
For those unable to join live, a replay will be available from April 1 through April 7, 2026, by calling 1-855-669-9658 (domestic) or 1-412-317-0088 (international) using access code 6331493. The webcast replay will also be archived on the company's website.
This announcement is important as it signals the upcoming release of key financial data for a company that plays a critical role in the cancer treatment landscape. American Shared Hospital Services provides turnkey solutions to cancer treatment centers, health systems, and cancer networks across North and South America. The company works closely with partners to develop and grow cancer service lines, enabling integrated cancer care in convenient local settings. Under health system partnerships, the company shares capital investment costs and profitability based on ownership interests.
The financial results conference call comes at a time when the company continues to expand its Gamma Knife, proton therapy, and advanced radiation therapy businesses. These growth initiatives involve risks and uncertainties, including economic conditions, variability of financial results between quarters, changes in CMS reimbursement rates or methodology, and the timing and financing of operations in new markets. As detailed in the company's SEC filings, including its Quarterly Report on Form 10-Q for the periods ended March 31, 2025, June 30, 2025, September 30, 2025, and the Annual Report on Form 10-K for the year ended December 31, 2024, these factors could affect financial condition and future plans.
Investors and industry observers will be watching for insights into the company's performance and outlook, particularly given the growing demand for advanced cancer treatments. The call provides a platform for management to address these topics and discuss strategic direction.
